Adelya F. Karimova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adelya F. Karimova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anna Brichkina
Institute of Systems Immunology, Center for Tumor Biology and Immunology, Philipps University of Marburg, Marburg, Germany
2 shared publications - Hans-Uwe Simon
Institute of Pharmacology University of Bern Bern Switzerland
2 shared publications Adelya R. Khalitova
Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
1 shared publication- Adelya R. Khalitova
Institute of Fundamental Medicine and Biology Kazan Federal University Kazan Russia
1 shared publication - Albert Anatolyevich Rizvanov
Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia
1 shared publication - Avanee Ketkar
Institute of Systems Immunology, Center for Tumor‐ and Immune Biology Philipps University of Marburg Marburg Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 28 February 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 220, 115332
Immunometabolism of tumor-associated macrophages: A therapeutic perspective
- 28 February 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 220, 115332
Top Cited PapersOpen AccessImmunometabolism of tumor-associated macrophages: A therapeutic perspective
- Open Access
- 20 June 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23730
In vitro functional assays to assess the reciprocal interplay between tumor cells and macrophages
Tumor‐associated macrophages (TAMs) are integral components of the tumor microenvironment. They are involved in various aspects of tumor cell biology, driving pathological processes such as tumor cell proliferation, metastasis, immunosuppression, and resistance to therapy. TAMs exert their tumorigenic effects by secreting growth factors, cytokines/chemokines, metabolites, and other soluble bioactive molecules. These mediators directly promote tumor cell proliferation and modulate interactions with immune and stromal cells, facilitating further tumor growth. As research into therapies targeting TAMs intensifies, there is a growing need for reliable methods to comprehend the impact of TAMs on cancer progression and to validate novel therapeutics directed at TAMs. The traditional “M1‐M2” macrophage classification based on transcriptional profiles of TAMs is not only too simplistic to describe their physiological roles, it also does not explain differences observed between mouse and human macrophages. In this context, methods that assess how TAMs influence tumor or immune cells, either through direct contact or the release of soluble factors, offer a more promising approach. We describe here comprehensive protocols for in vitro functional assays to study TAMs, specifically regarding their impact on the growth of lung cancer cells. We have applied these methods to both mouse and human macrophages, achieving similar outcomes in promoting the proliferation of cancer cells. This methodology can serve as a standardized approach for testing novel therapeutic approaches, targeting TAMs with novel immunotherapeutic compounds, or utilizing gene‐editing techniques. Taken together, the described methodology may contribute to our understanding of complex macrophage‐tumor interactions and support the development of innovative therapeutic strategies.
- 20 June 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23730
Open AccessIn vitro functional assays to assess the reciprocal interplay between tumor cells and macrophages
Tumor‐associated macrophages (TAMs) are integral components of the tumor microenvironment. They are involved in various aspects of tumor cell biology, driving pathological processes such as tumor cell proliferation, metastasis, immunosuppression, and resistance to therapy. TAMs exert their tumorigenic effects by secreting growth factors, cytokines/chemokines, metabolites, and other soluble bioactive molecules. These mediators directly promote tumor cell proliferation and modulate interactions with immune and stromal cells, facilitating further tumor growth. As research into therapies targeting TAMs intensifies, there is a growing need for reliable methods to comprehend the impact of TAMs on cancer progression and to validate novel therapeutics directed at TAMs. The traditional “M1‐M2” macrophage classification based on transcriptional profiles of TAMs is not only too simplistic to describe their physiological roles, it also does not explain differences observed between mouse and human macrophages. In this context, methods that assess how TAMs influence tumor or immune cells, either through direct contact or the release of soluble factors, offer a more promising approach. We describe here comprehensive protocols for in vitro functional assays to study TAMs, specifically regarding their impact on the growth of lung cancer cells. We have applied these methods to both mouse and human macrophages, achieving similar outcomes in promoting the proliferation of cancer cells. This methodology can serve as a standardized approach for testing novel therapeutic approaches, targeting TAMs with novel immunotherapeutic compounds, or utilizing gene‐editing techniques. Taken together, the described methodology may contribute to our understanding of complex macrophage‐tumor interactions and support the development of innovative therapeutic strategies.